HUP0104568A2 - Humán prosztata sejtvonalak a daganatok kezelésében - Google Patents
Humán prosztata sejtvonalak a daganatok kezelésébenInfo
- Publication number
- HUP0104568A2 HUP0104568A2 HU0104568A HUP0104568A HUP0104568A2 HU P0104568 A2 HUP0104568 A2 HU P0104568A2 HU 0104568 A HU0104568 A HU 0104568A HU P0104568 A HUP0104568 A HU P0104568A HU P0104568 A2 HUP0104568 A2 HU P0104568A2
- Authority
- HU
- Hungary
- Prior art keywords
- cells
- cell lines
- tumor
- normal
- cell
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 11
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000000735 allogeneic effect Effects 0.000 abstract 2
- 229940022399 cancer vaccine Drugs 0.000 abstract 2
- 238000001709 templated self-assembly Methods 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 229940038872 cell-based cancer vaccine Drugs 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 231100000636 lethal dose Toxicity 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A találmány sejtvonalból vagy sejtvonalakból álló termékeknekemlősökben és emberekben a rákbetegség kezeléséhez allogénimmunterápiás szerként történő használatára vonatkozik. Napjainkig azösszes sejtalapúrákvakcina-tanulmányok egy vonásban megegyeznek,nevezetesen a legalább néhány olyan TSA-t és/vagy TAA-t tartalmazósejtek használatának szándékában, melyek a beteg tumorjában lévőantigénekkel megegyeznek. A tumorsejteket minden esetben kiindulásipontként alkalmazzák, azzal az előfeltétellel, hogy a tumorsejtek csaka releváns TSA-kat vagy TAA-kat tartalmazzák, és a sejtek szövetieredete a betegben lévő tumor helyével egyezik. A találmány elsődlegestárgyköre a halhatatlanná tett normális, nem malignus sejtekhasználatára vonatkozik, amely allogén sejt rákvakcina-alapjakéntszolgál. A normális sejtek TSA-kkal vagy a TAA-k megfelelőkoncentrációjával nem rendelkeznek, ennélfogva meglepő, hogy az ittleírtak alapján a normális sejtek hatásos rákellenes vakcinák. Példáula prosztatarák esetében a vakcina alapja a prosztatából származó, egyvagy több különböző halhatatlanná tett sejtvonal és normális sejtvonalkombinációja lehet. Az emlősökben vagy az emberekben történő használatelőtt a replikáció megakadályozása érdekében a sejtvonalakat letálisdózisú 50-300 Gy gamma-sugárzásnak teszik ki. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9827104.2A GB9827104D0 (en) | 1998-12-10 | 1998-12-10 | New cancer treatments |
| PCT/GB1999/004129 WO2000033869A2 (en) | 1998-12-10 | 1999-12-09 | Use of human prostrate cell lines in cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0104568A2 true HUP0104568A2 (hu) | 2002-03-28 |
| HUP0104568A3 HUP0104568A3 (en) | 2004-05-28 |
Family
ID=10843926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0104568A HUP0104568A3 (en) | 1998-12-10 | 1999-12-09 | Human prostatic cell lines for cancer treatment |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US6972128B1 (hu) |
| EP (1) | EP1137422B1 (hu) |
| JP (2) | JP4949554B2 (hu) |
| KR (1) | KR20010090874A (hu) |
| AT (1) | ATE304365T1 (hu) |
| AU (1) | AU763485B2 (hu) |
| CA (1) | CA2354045C (hu) |
| CZ (1) | CZ300499B6 (hu) |
| DE (1) | DE69927286T2 (hu) |
| ES (1) | ES2249046T3 (hu) |
| GB (1) | GB9827104D0 (hu) |
| HU (1) | HUP0104568A3 (hu) |
| IL (2) | IL143296A0 (hu) |
| MX (1) | MXPA01005816A (hu) |
| NO (1) | NO327044B1 (hu) |
| NZ (1) | NZ512004A (hu) |
| PL (1) | PL201016B1 (hu) |
| WO (1) | WO2000033869A2 (hu) |
| ZA (1) | ZA200104164B (hu) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9827103D0 (en) * | 1998-12-10 | 1999-02-03 | Onyvax Ltd | New cancer treatments |
| GB9827104D0 (en) * | 1998-12-10 | 1999-02-03 | Onyvax Ltd | New cancer treatments |
| WO2000071156A2 (en) * | 1999-05-21 | 2000-11-30 | Onyvax Limited | New vaccine formulations-3 |
| DK1272617T3 (da) * | 2000-04-01 | 2011-08-22 | Onyvax Ltd | Prostata cellelinier og deres anvendelse |
| US6667479B2 (en) * | 2001-06-01 | 2003-12-23 | Raytheon Company | Advanced high speed, multi-level uncooled bolometer and method for fabricating same |
| US20050019336A1 (en) * | 2003-07-23 | 2005-01-27 | Dalgleish Angus George | Human prostate cell lines in cancer treatment |
| AU2004270113A1 (en) * | 2003-08-26 | 2005-03-17 | Becton, Dickinson And Company | Methods for intradermal delivery of therapeutics agents |
| KR101323540B1 (ko) | 2007-02-07 | 2013-10-29 | 사이단호진한다이비세이부쯔뵤우겐큐우카이 | 암의 치료제 |
| US20100255020A1 (en) * | 2007-11-20 | 2010-10-07 | Nec Corporation | Method for inducing cytotoxic t-cells, cytotoxic t-cell inducers, and pharmaceutical compositions and vaccines employing them |
| AU2009200767A1 (en) * | 2008-03-10 | 2009-09-24 | Aristocrat Technologies Australia Pty Limited | A gaming system and a method of gaming |
| EP2376089B1 (en) | 2008-11-17 | 2018-03-14 | The Regents of the University of Michigan | Cancer vaccine compositions and methods of using the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU677165B2 (en) * | 1991-10-04 | 1997-04-17 | Johns Hopkins University School Of Medicine, The | The regulation of systemic immune responses utilizing cytokines and antigens |
| JPH05246889A (ja) * | 1992-03-05 | 1993-09-24 | Seitai Chiyousetsu Kenkyusho:Kk | 制癌方法および制癌剤 |
| AU2370195A (en) * | 1994-04-28 | 1995-11-29 | Scott Freeman | Cell lines obtained by (in vivo) migration and by fusion with autoimmune cells |
| JP3201610B2 (ja) * | 1995-03-17 | 2001-08-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 腫瘍を処置する方法 |
| US5788963A (en) * | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| WO1997024132A1 (en) * | 1995-12-28 | 1997-07-10 | The Johns Hopkins University School Of Medicine | Allogeneic paracrine cytokine tumor vaccines |
| DE69721731T2 (de) * | 1996-02-02 | 2004-03-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immortalisierte menschliche prostata-epithelzellen und klone und ihre verwendungen zur untersuchung und therapie von prostata-krebs |
| GB9620350D0 (en) * | 1996-09-30 | 1996-11-13 | Maudsley David J | Cancer vaccine |
| US6207805B1 (en) * | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
| GB9827104D0 (en) * | 1998-12-10 | 1999-02-03 | Onyvax Ltd | New cancer treatments |
-
1998
- 1998-12-10 GB GBGB9827104.2A patent/GB9827104D0/en not_active Ceased
-
1999
- 1999-12-09 NZ NZ512004A patent/NZ512004A/en unknown
- 1999-12-09 WO PCT/GB1999/004129 patent/WO2000033869A2/en not_active Application Discontinuation
- 1999-12-09 ES ES99959542T patent/ES2249046T3/es not_active Expired - Lifetime
- 1999-12-09 MX MXPA01005816A patent/MXPA01005816A/es active IP Right Grant
- 1999-12-09 JP JP2000586359A patent/JP4949554B2/ja not_active Expired - Fee Related
- 1999-12-09 PL PL348828A patent/PL201016B1/pl not_active IP Right Cessation
- 1999-12-09 DE DE69927286T patent/DE69927286T2/de not_active Expired - Lifetime
- 1999-12-09 EP EP99959542A patent/EP1137422B1/en not_active Expired - Lifetime
- 1999-12-09 AT AT99959542T patent/ATE304365T1/de not_active IP Right Cessation
- 1999-12-09 AU AU16683/00A patent/AU763485B2/en not_active Ceased
- 1999-12-09 HU HU0104568A patent/HUP0104568A3/hu unknown
- 1999-12-09 KR KR1020017007096A patent/KR20010090874A/ko not_active Application Discontinuation
- 1999-12-09 IL IL14329699A patent/IL143296A0/xx active IP Right Grant
- 1999-12-09 CA CA2354045A patent/CA2354045C/en not_active Expired - Fee Related
- 1999-12-09 US US09/857,691 patent/US6972128B1/en not_active Expired - Lifetime
- 1999-12-09 CZ CZ20012032A patent/CZ300499B6/cs not_active IP Right Cessation
-
2001
- 2001-05-22 IL IL143296A patent/IL143296A/en not_active IP Right Cessation
- 2001-05-22 ZA ZA200104164A patent/ZA200104164B/en unknown
- 2001-05-29 NO NO20012634A patent/NO327044B1/no not_active IP Right Cessation
-
2005
- 2005-07-12 US US11/178,415 patent/US8034360B2/en not_active Expired - Fee Related
-
2011
- 2011-10-07 JP JP2011223318A patent/JP2012021028A/ja active Pending
- 2011-10-11 US US13/270,820 patent/US20120164099A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HURWITZ | The sun and sunscreen protection: recommendations for children | |
| HUP0102240A2 (hu) | Indigoid biszindolszármazékok alkalmazása ciklinfüggő kinázok gátlására szolgáló gyógyszer előállítására | |
| DE69408309D1 (de) | Mittel zum künstlichen sonnenbräunen und zum schutz der haut gegen uv-strahlen | |
| HUP0104568A2 (hu) | Humán prosztata sejtvonalak a daganatok kezelésében | |
| IL141434A0 (en) | Quinazoline derivatives | |
| BR0107643A (pt) | Composições e processos para a terapia e diagnóstico de c ncer de próstata | |
| HUP0104857A2 (hu) | Új rákkezelési módszerek | |
| BG101284A (en) | Compounds and methods for cancer treatment | |
| HUP0402067A2 (hu) | Oltóanyagok | |
| PL308217A1 (en) | Derivatives of 1-(oxo-acetyl)-piperidine-2-carboxylic as agents sensibilising multiple-drug-resistant cancer cells | |
| ATE404667T1 (de) | Chromatin-regulatorgene | |
| HUP9801167A2 (hu) | Triaromás vegyületek, azokat tartalmazó kompozíciók és alkalmazásuk | |
| DE69718734D1 (de) | Bicyclische aromatische verbindungen | |
| DE69434244D1 (de) | Verbesserte krebstherapie | |
| Riggs et al. | In vitro anticancer effects of a novel immunostimulant: keyhole limpet hemocyanin | |
| SE0300098D0 (sv) | Use of cyclin D1 inhibitors | |
| HUP0105281A2 (hu) | Rákellenes hatású benzaldehidszármazékok és gyógyászati alkalmazásuk | |
| TR200100637T2 (tr) | Yeni doğal ürün türevleri | |
| BR0208860A (pt) | Uso de um derivado de dextrano catiÈnico, método para a proteção de um indivìduo contra o dano em órgãos com limitação de dose, e, método para a proteção de um indivìduo contra dano renal | |
| HUP0302629A2 (hu) | Camptotechin és sztilbénszármazékok kombinációját tartalmazó gyógyszerkészítmények rák kezelésére | |
| WO2000033871A3 (en) | Use of human prostate tumour cell lines in cancer treatment | |
| HUP0203348A2 (hu) | Legalább egy NO szintáz inhibitor anyagot legalább egy foszfolipáz A2 inhibitor anyaggal együttesen tartalmazó készítmény és alkalmazása | |
| DK0707477T3 (da) | Anvendelse af Efaxoran og derivater deraf til fremstilling af lægemidler beregnet til behandling af neurodegenerative sygdo | |
| Bolla et al. | Controlled clinical trial in high metastatic risk carcinoma of the prostate comparing pelvic radiotherapy alone to pelvic radiotherapy plus LHRH analogue | |
| Tricarico | Ozone Therapy in periodontal diseae: preliminary considerations for the elaboration of the Guidelines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |